CO5261533A1 - Formulaciones parenterales liquidas estables libres de agua que comprenden sales de sodio o potasio de bencimidazoles sustituidos y polietilenglicol - Google Patents

Formulaciones parenterales liquidas estables libres de agua que comprenden sales de sodio o potasio de bencimidazoles sustituidos y polietilenglicol

Info

Publication number
CO5261533A1
CO5261533A1 CO00079671A CO00079671A CO5261533A1 CO 5261533 A1 CO5261533 A1 CO 5261533A1 CO 00079671 A CO00079671 A CO 00079671A CO 00079671 A CO00079671 A CO 00079671A CO 5261533 A1 CO5261533 A1 CO 5261533A1
Authority
CO
Colombia
Prior art keywords
polyethylene glycol
bencimidazols
substituted
include sodium
potassium salts
Prior art date
Application number
CO00079671A
Other languages
English (en)
Inventor
Mikael Brulls
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5261533A1 publication Critical patent/CO5261533A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una formulación líquida estable libre o casi libre de agua, que comprende polietilen glicol y una sal de sodio o de potasio de un inhibidor H , y K -ATPasa , yopcionalmente excipientes farmacéuticamente aceptables que son solubles en la formulación.K -ATPasa es omeprazol, lanzoprazol, pantoprazol y rabeprazol.
CO00079671A 1999-10-22 2000-10-19 Formulaciones parenterales liquidas estables libres de agua que comprenden sales de sodio o potasio de bencimidazoles sustituidos y polietilenglicol CO5261533A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903831A SE9903831D0 (sv) 1999-10-22 1999-10-22 Formulation of substituted benzimidazoles

Publications (1)

Publication Number Publication Date
CO5261533A1 true CO5261533A1 (es) 2003-03-31

Family

ID=20417464

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00079671A CO5261533A1 (es) 1999-10-22 2000-10-19 Formulaciones parenterales liquidas estables libres de agua que comprenden sales de sodio o potasio de bencimidazoles sustituidos y polietilenglicol

Country Status (36)

Country Link
US (1) US6730685B1 (es)
EP (1) EP1274427B1 (es)
JP (1) JP2003512327A (es)
KR (1) KR100785603B1 (es)
CN (1) CN1213751C (es)
AR (1) AR029005A1 (es)
AT (1) ATE304851T1 (es)
AU (1) AU782866B2 (es)
BG (1) BG65580B1 (es)
BR (1) BR0014895A (es)
CA (1) CA2425199C (es)
CO (1) CO5261533A1 (es)
CY (1) CY1106055T1 (es)
CZ (1) CZ20021375A3 (es)
DE (1) DE60022789T2 (es)
DK (1) DK1274427T3 (es)
EE (1) EE05175B1 (es)
ES (1) ES2246903T3 (es)
HK (1) HK1051142A1 (es)
HU (1) HUP0203121A3 (es)
IL (2) IL149107A0 (es)
IS (1) IS2196B (es)
MX (1) MXPA02003900A (es)
MY (1) MY131971A (es)
NO (1) NO329545B1 (es)
NZ (1) NZ518155A (es)
PL (1) PL199868B1 (es)
RU (1) RU2286782C2 (es)
SE (1) SE9903831D0 (es)
SI (1) SI1274427T1 (es)
SK (1) SK286266B6 (es)
TR (1) TR200201103T2 (es)
TW (1) TWI236372B (es)
UA (1) UA74347C2 (es)
WO (1) WO2001028558A1 (es)
ZA (1) ZA200202905B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271182B2 (en) * 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
WO2002015908A1 (fr) * 2000-08-18 2002-02-28 Takeda Chemical Industries, Ltd. Injections
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2848555B1 (fr) * 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
CA2512928A1 (en) * 2003-02-24 2004-09-02 Mitsubishi Pharma Corporation The enantiomer of tenatoprazole and the use thereof in therapy
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060089376A1 (en) * 2004-10-27 2006-04-27 Joshi Ramesh A Tenatoprazole salts and process of preparation thereof
EP2018151A4 (en) * 2006-05-09 2012-07-18 Astrazeneca Ab PARENTERAL FORMULATION COMPRISING AN INHIBITOR OF THE PROTON PUMP STERILIZED IN ITS FINAL CONTAINER BY IONIZING RADIATION
CN100411613C (zh) * 2006-12-08 2008-08-20 中国药科大学 一种奥美拉唑速释固体制剂及其制备方法
JP6698651B2 (ja) 2014-11-13 2020-05-27 スリーエム イノベイティブ プロパティズ カンパニー 試料中の細菌ａｔｐを検出するためのａｔｐ−ジホスホヒドロラーゼを含むキット
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
DK399389A (da) * 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
KR930000861B1 (ko) 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
DK0652751T3 (da) 1992-07-28 1996-11-18 Astra Ab Injektionspræparat og injektions-kit indeholdende omeprazol og dens analoger
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
TW359614B (en) 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions

Also Published As

Publication number Publication date
EP1274427A1 (en) 2003-01-15
CN1213751C (zh) 2005-08-10
HUP0203121A2 (hu) 2003-01-28
JP2003512327A (ja) 2003-04-02
SK5392002A3 (en) 2002-10-08
MY131971A (en) 2007-09-28
ATE304851T1 (de) 2005-10-15
TWI236372B (en) 2005-07-21
AR029005A1 (es) 2003-06-04
KR100785603B1 (ko) 2007-12-14
IL149107A (en) 2008-04-13
BG106602A (en) 2002-12-29
IL149107A0 (en) 2002-11-10
MXPA02003900A (es) 2002-09-30
SE9903831D0 (sv) 1999-10-22
IS2196B (is) 2007-01-15
US6730685B1 (en) 2004-05-04
NO20021860L (no) 2002-05-21
PL354926A1 (en) 2004-03-22
AU1182301A (en) 2001-04-30
EP1274427B1 (en) 2005-09-21
SI1274427T1 (sl) 2006-02-28
HK1051142A1 (en) 2003-07-25
BR0014895A (pt) 2002-06-18
CY1106055T1 (el) 2011-04-06
CZ20021375A3 (cs) 2002-09-11
ES2246903T3 (es) 2006-03-01
RU2286782C2 (ru) 2006-11-10
HUP0203121A3 (en) 2004-01-28
DK1274427T3 (da) 2005-12-27
EE05175B1 (et) 2009-06-15
BG65580B1 (bg) 2009-01-30
PL199868B1 (pl) 2008-11-28
DE60022789D1 (de) 2006-02-02
DE60022789T2 (de) 2006-06-22
NZ518155A (en) 2004-07-30
AU782866B2 (en) 2005-09-01
NO20021860D0 (no) 2002-04-19
ZA200202905B (en) 2003-07-14
EE200200204A (et) 2003-04-15
IS6347A (is) 2002-04-17
CA2425199A1 (en) 2001-04-26
SK286266B6 (sk) 2008-06-06
NO329545B1 (no) 2010-11-08
CA2425199C (en) 2010-12-07
WO2001028558A1 (en) 2001-04-26
CN1382048A (zh) 2002-11-27
KR20020059637A (ko) 2002-07-13
TR200201103T2 (tr) 2002-08-21
UA74347C2 (uk) 2005-12-15

Similar Documents

Publication Publication Date Title
CO5261533A1 (es) Formulaciones parenterales liquidas estables libres de agua que comprenden sales de sodio o potasio de bencimidazoles sustituidos y polietilenglicol
LU91363I2 (fr) Méthoxy polyéthylène glycol-époétine bêta et ses sels pharmaceutiquement acceptables (MIRCERA)
ATE303809T1 (de) Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
NO995809L (no) Farmasoeytisk formulering av omeprazol
DK1218374T3 (da) Farmaceutisk aktive sulfonamidderivater
ES2176206T3 (es) Derivados de ciclodextrinas que muestran solubilidad incrementada en el agua y utilizacion de los mismos.
NO970935L (no) Parenteralt preparat av tirilazad og ko-lösningsmiddel
TR199903098T2 (xx) �midozil-siklik asetaller
DK1221919T3 (da) Oftalmisk lægemiddeladministrationsanordning
SE9902386D0 (sv) New formulation
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
DK39798A (da) Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
AR002702A1 (es) Formulación farmacéutica oral estable conteniendo un compuesto de bencimidazol labil en medio ácido su procedimiento de obtención y sus formulaciones galenicas
NL1014040A1 (nl) Koppelhulpstuk voor geheugenopslaginrichtingen.
RS50245B (sr) Gastroprotektovane mikrogranule omeprazola, postupak za proizvodnju i farmaceutski preparati
SE0104203D0 (sv) Farmaceutiska formuleringar och metoder innefattande intranasalt morfin
HRP20010878B1 (en) Ziprasidone suspension
DK1112060T3 (da) Doseringsform anvendende flydende formulering
NO20031909L (no) Selvemulgerende, orale doseringsformuleringer av pyranon protease-inhibitorer
ES2163461T3 (es) Procedimiento para la obtencion de comprimidos efervescentes.
NO20010863L (no) Nye orale formuleringer for 5-HT4-agonister eller - antagonister
ATE469644T1 (de) Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
IT1319210B1 (it) Pellicola per la somministrazione dermica e transdermica di principiattivi.

Legal Events

Date Code Title Description
FG Application granted